ProSomnus SPAC Presentation Deck

ProSomnus Efficacy Comparable to CPAP for Mild and Moderate OSA PROSOMNUS SLEEP TECHNOLOGIES Precision customized oral devices continue to outperform legacy oral devices while achieving rates consistent with CPAP EFFICACY FOR MILD/MODERATE OSA PROSOMNUS SLEEP TECHNOLOGIES CPAP Upper Airway Stimulation Legacy OAT 1 2 2 N/A (Severe Only) 56% 94% 90% Efficacy does not factor in adherence challenges associated with CPAP 1. Mosca et al. JCSM 2022; 18(3):911-919. 2. Dieltjens M, Vanderveken O. Oral Appliances in Obstructive Sleep Apnea. Healthcare (Basel). 2019 Nov 8 3. Benjafield AV, et al. 2019 Aug 7, assumed even split between moderate and severe as provided by management DISEASE STATE BY SEVERITY³ ProSomnus Precision OAT a Leading Option for ~80% of Sufferers Severe, 21% Moderate, 21% Mild, 58% PROSOMNUS'S SEVERE INDICATION OPPORTUNITY ▪ ProSomnus has received FDA approval for a study protocol to investigate a severe OSA indication Patient enrollment expected Q2 '22 ▪ Retrospective cohort analysis demonstrates that ProSomnus can safely and effectively treat severe OSA ■ Medical insurance guidelines already support treatment of severe OSA with ProSomnus 13 STRICTLY CONFIDENTIAL

View entire presentation